Technical Analysis for FATE - Fate Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 18.97 3.49% 0.64
FATE closed up 3.49 percent on Friday, May 24, 2019, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical FATE trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
New Uptrend Bullish 3.49%
Upper Bollinger Band Walk Strength 0.80%
Outside Day Range Expansion 0.80%
Upper Bollinger Band Touch Strength 0.80%
180 Bullish Setup Bullish Swing Setup -1.04%
Upper Bollinger Band Walk Strength -1.04%
Upper Bollinger Band Walk Strength 2.87%
Inside Day Range Contraction 2.87%
Upper Bollinger Band Touch Strength 2.87%

Older signals for FATE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person's lifespan; and SSC modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person's lifespan. The company's products include ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical trials for hematologic malignancies in adult patients. It also plans to conduct clinical trials of ProHema for hematopoietic reconstitution in hematologic malignancies and lysosomal storage disorders in pediatric patients. In addition, the company is developing Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Biotechnology Biopharmaceutical Life Sciences Biology Stem Cells Hematologic Malignancies Orphan Diseases Cord Blood Induced Stem Cells Adult Stem Cell Lysosomal Storage Disorders
Is FATE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.04
52 Week Low 8.64
Average Volume 689,688
200-Day Moving Average 14.9182
50-Day Moving Average 17.3946
20-Day Moving Average 17.714
10-Day Moving Average 18.438
Average True Range 1.0178
ADX 26.57
+DI 26.9366
-DI 10.1485
Chandelier Exit (Long, 3 ATRs ) 16.9866
Chandelier Exit (Short, 3 ATRs ) 19.0534
Upper Bollinger Band 19.6839
Lower Bollinger Band 15.7441
Percent B (%b) 0.82
BandWidth 22.241165
MACD Line 0.5191
MACD Signal Line 0.3883
MACD Histogram 0.1308
Fundamentals Value
Market Cap 785.63 Million
Num Shares 41.4 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -19.76
Price-to-Sales 42.87
Price-to-Book 3.19
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.01
Resistance 3 (R3) 19.95 19.54 19.83
Resistance 2 (R2) 19.54 19.28 19.57 19.77
Resistance 1 (R1) 19.26 19.12 19.40 19.32 19.72
Pivot Point 18.85 18.85 18.93 18.88 18.85
Support 1 (S1) 18.57 18.59 18.71 18.63 18.22
Support 2 (S2) 18.16 18.43 18.19 18.17
Support 3 (S3) 17.88 18.16 18.11
Support 4 (S4) 17.94